<author><surname>Swerdlow</surname> <given-names>SH</given-names> </author><author><surname>Campo</surname> <given-names>E</given-names> </author><author><surname>Harris</surname> <given-names>NL</given-names> </author><source>WHO classification of tumours of haematopoietic and lymphoid tissues</source><year>2008</year><other>Lyon</other><publisher>IARC</publisher>
<author><surname>Tefferi</surname> <given-names>A</given-names> </author><author><surname>Thiele</surname> <given-names>J</given-names> </author><author><surname>Orazi</surname> <given-names>A</given-names> </author><author><surname>Kvasnicka</surname> <given-names>HM</given-names> </author><author><surname>Barbui</surname> <given-names>T</given-names> </author><author><surname>Hanson</surname> <given-names>CA</given-names> </author><author><surname>Barosi</surname> <given-names>G</given-names> </author><author><surname>Verstovsek</surname> <given-names>S</given-names> </author><author><surname>Birgegard</surname> <given-names>G</given-names> </author><author><surname>Mesa</surname> <given-names>R</given-names> </author><author><surname>Reilly</surname> <given-names>JT</given-names> </author><author><surname>Gisslinger</surname> <given-names>H</given-names> </author><author><surname>Vannucchi</surname> <given-names>AM</given-names> </author><author><surname>Cervantes</surname> <given-names>F</given-names> </author><author><surname>Finazzi</surname> <given-names>G</given-names> </author><author><surname>Hoffman</surname> <given-names>R</given-names> </author><author><surname>Gilliland</surname> <given-names>DG</given-names> </author><author><surname>Bloomfield</surname> <given-names>CD</given-names> </author><author><surname>Vardiman</surname> <given-names>JW</given-names> </author><title>Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel</title><source>Blood</source><year>2007</year><volume>110</volume><issue>4</issue><fpage>1092</fpage><lpage>1097</lpage>
<author><surname>Thiele</surname> <given-names>J</given-names> </author><author><surname>Kvasnicka</surname> <given-names>HM</given-names> </author><author><surname>Facchetti</surname> <given-names>F</given-names> </author><author><surname>Franco</surname> <given-names>V</given-names> </author><author><surname>Walt</surname> <given-names>J</given-names> </author><author><surname>Orazi</surname> <given-names>A</given-names> </author><title>European consensus on grading bone marrow fibrosis and assessment of cellularity</title><source>Haematologica</source><year>2005</year><volume>90</volume><fpage>1128</fpage><lpage>1132</lpage>
<author><surname>Fend</surname> <given-names>F</given-names> </author><author><surname>Horn</surname> <given-names>T</given-names> </author><author><surname>Koch</surname> <given-names>I</given-names> </author><author><surname>Vela</surname> <given-names>T</given-names> </author><author><surname>Orazi</surname> <given-names>A</given-names> </author><title>Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm</title><source>Leuk Res</source><year>2008</year><volume>32</volume><issue>12</issue><fpage>1931</fpage><lpage>1935</lpage>
<author><surname>Wardrop</surname> <given-names>D</given-names> </author><author><surname>Steensma</surname> <given-names>DP</given-names> </author><title>Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?</title><source>Br J Haematol</source><year>2009</year><volume>144</volume><issue>6</issue><fpage>809</fpage><lpage>817</lpage>
<author><surname>Ades</surname> <given-names>L</given-names> </author><author><surname>Boehrer</surname> <given-names>S</given-names> </author><author><surname>Prebet</surname> <given-names>T</given-names> </author><author><surname>Beyne-Rauzy</surname> <given-names>O</given-names> </author><author><surname>Legros</surname> <given-names>L</given-names> </author><author><surname>Ravoet</surname> <given-names>C</given-names> </author><author><surname>Dreyfus</surname> <given-names>F</given-names> </author><author><surname>Stamatoullas</surname> <given-names>A</given-names> </author><author><surname>Chaury</surname> <given-names>MP</given-names> </author><author><surname>Delaunay</surname> <given-names>J</given-names> </author><author><surname>Laurent</surname> <given-names>G</given-names> </author><author><surname>Vey</surname> <given-names>N</given-names> </author><author><surname>Burcheri</surname> <given-names>S</given-names> </author><author><surname>Mbida</surname> <given-names>RM</given-names> </author><author><surname>Hoarau</surname> <given-names>N</given-names> </author><author><surname>Gardin</surname> <given-names>C</given-names> </author><author><surname>Fenaux</surname> <given-names>P</given-names> </author><title>Efficacy and safety of lenalidomide in intermediate-2-or high risk myelodysplastic syndromes (MDS) with 5q deletion: Results of a phase II study</title><source>Blood</source><year>2009</year><volume>113</volume><issue>17</issue><fpage>3947</fpage><lpage>3952</lpage>